Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Advanced Research Center Inc.

Neither a doctor nor a teaching hospital

Research payments

$968,598

204 payments

Through program year 2024, Advanced Research Center Inc. is reported as receiving $968,598 in research payments, across 204 payments.

By program year

4 rows
Year Kind Amount Payments
2024 Research $56,178 18
2023 Research $540,586 166
2022 Research $369,770 18
2021 Research $2,064 2

Breakdown

Who paid Research payments · program years 2021–2024
  1. Sumitomo Pharma America, Inc. $535,086 165 payments
  2. Sunovion Pharmaceuticals Inc. $370,522 18 payments
  3. Neurocrine Biosciences, Inc. $31,237 17 payments
  4. Amgen Inc. $24,942 1 payment
  5. Currax Pharmaceuticals LLC $6,811 3 payments
Studies the money was for Research payments · program years 2021–2024
  1. A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia $368,459 16 payments
  2. A Randomized Double-blind Parallel-group Placebocontrolled Fixed-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia $215,780 5 payments
  3. A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. $163,774 34 payments
  4. A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication $127,367 112 payments
  5. A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia $31,237 17 payments
  6. P2 Dax in Derm/Anti-Syn Inflam Myositis $24,942 1 payment
  7. An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia $22,735 8 payments
  8. 17-AVP-825-301_Clinical Operations $5,500 1 payment
  9. A Randomized Double-blind Parallel-group Placebo-controlled Fixed-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia $5,430 6 payments
  10. A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia $2,064 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record